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Abstract 
In multicellular organisms, gene regulatory circuits generate thousands of molecularly distinct, 
mitotically heritable states, through the property of multistability. Designing synthetic 
multistable circuits would provide insight into natural cell fate control circuit architectures and 15 
allow engineering of multicellular programs that require interactions among cells in distinct 
states. Here we introduce MultiFate, a naturally-inspired, synthetic circuit that supports long-
term, controllable, and expandable multistability in mammalian cells. MultiFate uses engineered 
zinc finger transcription factors that transcriptionally self-activate as homodimers and mutually 
inhibit one another through heterodimerization. Using model-based design, we engineered 20 
MultiFate circuits that generate up to seven states, each stable for at least 18 days. MultiFate 
permits controlled state-switching and modulation of state stability through external inputs, and 
can be easily expanded with additional transcription factors. Together, these results provide a 
foundation for engineering multicellular behaviors in mammalian cells. 
  25 
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Multistability is one of the hallmarks of multicellular life, allowing genetically identical cells to 
exist in thousands of molecularly distinct and mitotically stable cell types or states (1–4). 
Understanding natural multistable circuits and engineering synthetic ones have been longstanding 
challenges in developmental and synthetic biology (5–22). While key regulatory interactions have 5 
been identified in some natural fate control circuits, it generally remains unclear what minimal 
circuitry is sufficient to generate the observed multistability. On the synthetic side, engineered 
multistable circuits would provide a foundation for synthetic developmental and therapeutic 
circuits that could generate a spectrum of designed cell types with specialized functions. However, 
previous efforts in mammalian cells have been limited to two-state systems and used architectures 10 
that cannot be easily expanded to larger numbers of states (8, 9, 12). To address both issues, we 
sought to engineer a synthetic multistable circuit in mammalian cells based on prevalent features 
of natural fate control systems.  
An ideal synthetic multistable system would allow cells to remain in any of a set of distinct 
expression states over extended timescales of many cell cycles, despite biological noise. In 15 
addition, it would provide three key capabilities exhibited by its natural counterparts (Fig. 1A): 
First, it would permit transient external inputs to switch cells between states, similar to the way 
signaling pathways direct fate decisions during development (23). Second, it would support control 
over the number and stability of different states, and enable irreversible transitions, similar to those 
that occur during natural differentiation (20, 24). Third, it would be expandable (scalable), so that 20 
one could increase the number of states by introducing additional components without re-
engineering an existing functional circuit, analogous to expansions in the number of cell types and 
states that have occurred during evolution (25, 26).  
Natural mammalian multistable circuits provide inspiration for such a synthetic architecture (Fig. 
1B) (27–37). For example, during myogenesis, muscle regulatory factors such as MyoD 25 
heterodimerize with E proteins to activate their own expression and the broader myogenesis 
program, while Id family proteins heterodimerize with muscle regulatory factors or E proteins to 
disrupt this process (34–36). Similarly, during embryogenesis, Sox2 and Sox17 competitively 
interact with the pluripotency regulator Oct4 to control the early differentiation decision between 
pluripotency and endodermal differentiation (31, 32). These and other circuits thus appear to use 30 
transcription factors that autoregulate their own expression and cross-regulate each other’s 
expression, and competitively interact to form a variety of homodimers, heterodimers, and higher 
order multimeric forms. Related combinations of positive autoregulation and cross-inhibition 
could extend multistability behaviors beyond bistability and generate bifurcation dynamics that 
explain the partial irreversibility of cell differentiation (11, 16, 38–41). Nevertheless, it remains 35 
unclear whether these natural architectures could be adapted to enable synthetic multistability. 
Here, we show how a synthetic multistable system based on principles derived from natural cell 
fate control systems can generate robust, controllable, expandable multistability in mammalian 
cells. 
Results 40 
The MultiFate circuit architecture generates diverse types of multistability through a set of 
promiscuously interacting, autoregulatory dimer-dependent transcription factors.	
Inspired by natural fate control circuits, we designed the MultiFate system, in which transcription 
factors homodimerize to positively autoregulate their own expression, and heterodimerize to 
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mutually inhibit each other’s transcriptional activity (Fig. 1C). The transcription factors share a 
common dimerization domain, allowing them to competitively form both homodimers and 
heterodimers. Further, the promoter of each transcription factor gene contains binding sites that 
can be strongly bound only by the homodimeric form of its own protein, allowing homodimer-
dependent self-activation. By contrast, heterodimers do not efficiently bind to any promoter in this 5 
design. Heterodimerization thus acts to mutually inhibit the activity of both constituent 
transcription factors.  
Mathematical modeling shows how the MultiFate architecture provides each of the desired 
capabilities described above (Fig. 1A) in physiologically reasonable parameter regimes (Box 1, 
Table S4, Supplementary Materials). A MultiFate circuit with just two transcription factors, 10 
designated MultiFate-2, can produce diverse types of multistability containing 2, 3 or 4 stable fixed 
points depending on protein stability and other parameter values (Fig. 1C, Fig. S1A). In particular, 
a regime designated type II tristability, that includes stable states expressing either A, B, or both, 
is analogous to multilineage priming in uncommitted progenitor cells, with the double positive 
state playing the role of a multipotent progenitor (42–50). In the model, transient expression of 15 
one transcription factor can switch cells between states (Fig. S3, Movie S1). Reducing the protein 
stability of transcription factors can cause bifurcations that selectively destabilize specific states 
(Fig. 1C). Finally, the model is expandable: addition of a new transcription factor to the MultiFate-
2 model generates a three transcription factor “MultiFate-3” circuit that supports additional stable 
states with the same parameter values (Fig. 1D, Fig. S2A). Together, these modeling results 20 
suggest that the MultiFate architecture can support a rich array of multistable behaviors. 
Engineered zinc fingers enable homodimer-dependent activation and heterodimer-
dependent inhibition. 
Synthetic zinc finger (ZF) transcription factors provide an ideal platform to implement the 
MultiFate circuit. Zinc finger DNA-binding domains can be assembled from individual zinc 25 
fingers to recognize target DNA binding sites with high specificity (51). When fused with a 
transcriptional activation domain, the resulting zinc finger transcription factors can activate gene 
expression when bound to its promoter (52–55). Further, engineered ZF DNA-binding domain 
containing three fingers bind weakly as monomers to 9bp target sites, but can bind much more 
strongly as homodimers to 18bp tandem binding site pairs (56). This property allows homodimer-30 
dependent transcriptional activity and potentially allows inhibition through heterodimerization.  
To engineer ZF transcription factors, we started with ZF-GCN4-AD, a synthetic transcription 
factor containing the ErbB2 ZF DNA-binding domain fused to a GCN4 homodimerization domain 
and a VP48 transcriptional activation domain (Fig. 2A) (56). As a monomeric (non-dimerizing) 
control, we also constructed a variant of this protein lacking GCN4, termed ZF-AD. To assay their 35 
transcriptional activity, we constructed a reporter containing two repeats of 18bp tandem binding 
site pairs driving the expression of a Citrine fluorescent protein (56). We then co-transfected each 
of the transcription factors together with the reporter and an mTagBFP2 co-transfection marker 
into CHO-K1 cells, and analyzed Citrine expression by flow cytometry 36 hours later (Fig. 2A, 
Fig. S4A, Supplementary Materials). The Wild-type (WT) ZF-GCN4-AD factors strongly 40 
activated the reporter, as desired, while the monomeric variant ZF-AD exhibited weaker, but still 
undesirable, basal activity (Fig. 2A, Fig. S4B). Following early structural work and recent 
advances in zinc finger engineering (52, 57–59), we incorporated arginine-to-alanine mutations at 
key positions in the ZF known to impact DNA binding, which decreased background monomeric 
activity without reducing foreground homodimer activity (bars within red square in Fig. 2A, Fig. 45 
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S4B). Further, we replaced the GCN4 with the FKBP12F36V (FKBP) homodimerization domain 
(60). The resulting FKBP-ZF-AD factor allows dose-dependent control of dimerization with the 
activating drug AP1903 (Fig. 2B). Finally, using this general design, we constructed eight 
additional dimer-dependent ZF transcription factors, and validated orthogonal DNA-binding 
specificities for four of them (Fig. S4C). Together, these results provided a set of orthogonal, 5 
externally controllable, homodimer-dependent ZF transcription factors.  
The MultiFate circuit design requires that each transcription factor positively autoregulates its own 
expression in a homodimer-dependent manner. To validate this capability, we designed a self-
activation construct (Fig. 2C, left), in which a transcription factor with FKBP dimerization domain 
is expressed from a promoter containing multiple repeats of its own 18bp homodimeric binding 10 
site (Table S1). This construct allowed independent Dox-inducible activation through upstream 
Tet3G (Takara Bio) binding sites. It also incorporated a dihydrofolate reductase (DHFR) degron 
(61), which can be inhibited by the drug trimethoprim (TMP), at the C-terminus of transcription 
factor, permitting control of protein stability. Thus, it allowed independent control of dimerization, 
expression, and degradation. To enable dynamic single-cell readout of expression, we also 15 
incorporated a destabilized mCitrine fluorescent protein on the same construct. Finally, we 
integrated this construct into Tet3G-expressing CHO-K1 cells, generating a stable polyclonal 
population for further analysis (Table S2, Supplementary Materials).  
To test for positive autoregulation, we transiently induced transcription factor expression for 24 
hours with Dox, and then withdrew Dox and checked whether cells could sustain circuit activation, 20 
at different dimerization strengths and protein stability, controlled by AP1903 and TMP, 
respectively. In the presence, but not the absence, of AP1903, cells exhibited a bimodal distribution 
of mCitrine fluorescence, with well-separated peaks (Fig. 2C, middle and right), consistent with 
dimer-dependent positive autoregulation in a subset of cells. TMP, by stabilizing transcription 
factors, also promoted self-activation in a dose-dependent manner (Fig. 2C, Fig. S5A). Together, 25 
these results show that a single self-activating dimer-dependent transcription factor can generate 
bimodal dynamics in a controllable manner.  
MultiFate’s final requirement is the ability of one transcription factor to effectively inhibit another 
through formation of inactive heterodimers. To test this, we selected monoclonal cell lines 
expressing the self-activating circuit, and then stably integrated constructs expressing proteins with 30 
a different ZF DNA-binding domain and a matching or mismatching dimerization domain (Table 
S1, Table S2, Supplementary Materials). Only proteins with matching dimerization domains 
inhibited the self-activating transcription factor, consistent with inhibition through 
heterodimerization (Fig. 2D, Fig. S5B). Taken together, these results provided a set of engineered 
ZF transcription factors that exhibit homodimer-dependent activation and heterodimeric inhibition 35 
with external control of dimerization and protein stability.  
The MultiFate-2 circuit generates tristability.	
To construct a complete MultiFate circuit, we selected two dimer-dependent transcription factors, 
henceforth designated A and B, with distinct DNA binding specificities but the same FKBP 
homodimerization domain (Table S1, Supplementary Materials), and expressed them from 40 
promoters containing multiple repeats of their corresponding 18bp homodimeric binding sites. The 
promoters also incorporated Tet3G or ERT2-Gal4 response elements (62) to allow independent 
external induction. A and B were co-expressed with destabilized mCherry or mCitrine fluorescent 
proteins, respectively, for visualization (Fig. 3A). We stably integrated both genes simultaneously 
in CHO-K1 cells expressing Tet3G and ERT2-Gal4 proteins, and further characterized three stable 45 
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monoclonal cell lines, designated MultiFate-2.1, MultiFate-2.2 and MultiFate-2.3 with different 
promoter configurations (Table S2, Supplementary Materials).  
We next sought to test whether MultiFate circuits support multistability in general and, more 
specifically, whether they could operate in the type II tristability regime, which exhibits features 
resembling multilineage priming and permits irreversible bifurcations to bistability regime to 5 
generate hysteresis (42–50) (Box 1). We activated the circuit by transferring MultiFate-2.1 cells 
to media containing AP1903 and TMP, allowing dimerization and stabilizing the transcription 
factors. As expected in the regime of type II tristability (Box 1, Fig. 1C), cells went from low 
expression of both transcription factors (OFF state) to one of three distinct states, with either A, 
B, or both transcription factors highly expressed (Fig. 3B), which we designated as A-only, B-only 10 
and A+B states, respectively. These states were well separated, by ~25-50 fold differences in either 
mCherry or mCitrine expression. To assess their stability, we sorted cells from each of these states 
and cultured them continuously for 18 days (Supplementary Materials). Strikingly, nearly all cells 
remained in the sorted state for this extended period (Fig. 3C, Fig. S6). Stability required the 
positive autoregulatory circuit, as withdrawal of AP1903 and TMP collapsed expression of both 15 
factors within 2 days (Fig. S6). Similar overall behavior was also observed in MultiFate-2.2 and 
MultiFate-2.3 (Fig. 3C, Fig. S7 and Fig. S8A). All three MultiFate-2 cell lines thus exhibited 
dynamics strikingly consistent with type II tristable behavior (Fig. 1C). 
Time-lapse imaging provided a more direct view of multistability. We cultured single cells from 
different initial states in the same well and imaged them as they developed into colonies (Fig. 3D). 20 
In almost all colonies (132/134), all cells maintained their initial states for the full duration of the 
movie, at least 5 days or 7-8 cell cycles (Fig. 3D, Fig. S9, Movie S2). Together with the flow 
cytometry analysis, these results demonstrate that all three MultiFate-2 lines can sustain long-term 
tristability.  
MultiFate-2 supports modulation of state stability and allows controlled state-switching.	25 
In natural cell fate control systems, destabilization of multipotent states has been suggested to 
facilitate irreversible transitions into differentiated fates (16, 41). Similarly, in the MultiFate-2 
model, reducing protein stability specifically destabilizes the A+B state, shifting the system from 
type II tristability to bistability (Fig. 1C). To test whether this predicted bifurcation would occur 
in the experimental system, we transferred A-only, B-only and A+B cells from media containing 30 
high TMP concentrations (“High TMP”) to similar media with reduced TMP concentrations (“Low 
TMP”), which decreases protein stability by permitting degron function.  
As predicted, reducing protein stability selectively destabilized the A+B state, but not the A-only 
and B-only states (Fig. 3C, Low TMP columns), causing cells to continuously transit from the 
destabilized A+B state to the stable A-only or B-only states (Fig. S6, Bottom). Different MultiFate-35 
2 cell lines exhibited different transition biases, reflecting clone-specific asymmetries in the 
experimental MultiFate-2 systems, in a manner consistent with an asymmetric MultiFate model 
(Movie S3, Supplementary Materials). Also as predicted, the OFF state remained unstable in the 
Low TMP condition, although cells exited the unstable OFF state more slowly than they did under 
the High TMP condition (Fig. 3C, OFF row). Reduced protein stability thus generated the 40 
predicted tristable-to-bistable bifurcation.  
The ability of a transient stimulus to trigger an irreversible fate change is a hallmark of many cell 
fate control systems, including oocyte maturation (20), and exit from pluripotency (24). In the 
model, transiently reducing protein stability produces an irreversible (hysteretic) response: cells 
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initially in the A+B state transit to A-only or B-only states when protein stability is reduced, and 
remain there, rather than return to the A+B state, when protein stability is restored to its initial 
value. Stochastic simulations of single cell dynamics exhibit this hysteretic behavior (Fig. 3E, top; 
Movie S3). To test whether hysteretic dynamics occur in the experimental system, we analyzed 
cell populations in the MultiFate-2.1 line after reducing TMP concentration and then restoring it 5 
to its initial high concentration. Indeed, escape from the destabilized A+B state was irreversible, 
as cells remained in the A-only or B-only state even after they were transferred back to the High 
TMP condition (Fig. 3E, bottom; Fig. S6). MultiFate’s ability to support irreversible transitions 
allows it to produce behaviors resembling stem cell differentiation.  
Finally, we asked to what extent we could deliberately switch cells from one state to another 10 
through transient perturbations. In MultiFate-2.3, the A and B genes are independently inducible 
by 4-hydroxy-tamoxifen (4-OHT) and Dox (Table S2). Transient Dox treatment transitioned A-
only cells to the B-only state within 6 days (Fig. 3F, top). During switching, cells briefly expressed 
both proteins at elevated levels (Fig. S8B), consistent with model predictions (Fig. S3, Movie S1). 
Conversely, transient 4-OHT induction of A expression transitioned B-only cells to the A-only 15 
state in a similar manner (Fig. 3F, bottom). MultiFate-2 thus allows controlled state-switching with 
transient inputs. Taken together, these results demonstrate that MultiFate-2 circuits allow 
modulation of state stability, irreversible (hysteretic) cell state transitions, and direct control of 
state-switching with external inputs. 
MultiFate is expandable.	20 
Because MultiFate circuits implement mutual inhibition among transcription factors through 
heterodimerization, MultiFate circuits can be expanded simply by adding additional transcription 
factors, without re-engineering existing components. In the model, adding a third transcription 
factor to a MultiFate-2 circuit produces a range of new stability regimes containing 3, 4, 6, 7, or 8 
stable fixed points, depending on parameter values (Fig. 1D, Fig. S2, Movie S4, Supplementary 25 
Materials).  
Can experimental MultiFate-2 circuits be similarly expanded? To answer this question, we stably 
integrated a third ZF transcription factor, denoted C, containing the same FKBP dimerization 
domain as A and B, co-expressed with a third fluorescent protein, mTurqoise2, into the MultiFate-
2.2 cell line (Fig. 4A, Table S2, Supplementary Materials). After addition of AP1903 and TMP, 30 
the resulting MultiFate-3 cells populated 7 distinct clusters, termed A-only, B-only, C-only, A+B, 
A+C, B+C, and A+B+C states (Fig. 4B). Most cells went to the B-only state (79.5%±0.3%), 
reflecting asymmetries within the circuit (e.g. higher basal expression at B cassettes). The set of 
stable states, and the absence of a stable OFF state with no proteins expressed, strikingly resembled 
the type II septastable regime at high protein stability (Fig. 1D, Fig. S2A). To assess the stability 35 
of these states, we sorted cells from each of the seven states, and continuously cultured them in 
media containing AP1903 and TMP, analyzing the culture every 3 days by flow cytometry. 
Remarkably, each of the seven states was stable for the full 18-day duration of the experiment 
(Fig. 4B, High TMP columns; Fig. S10). Long-term stability required AP1903 and TMP, as 
expected (Fig. S13). Finally, cells from each state could be reset by withdrawal of AP1903 and 40 
TMP and then re-differentiated into all of the states when AP1903 and TMP were added back (Fig. 
S13). This indicates that the observed stability is not the result of a mixture of clones permanently 
locked into distinct expression states.  
To directly visualize the septastable dynamics of MultiFate-3, we co-cultured single cells sorted 
from each of the seven states and performed live imaging as they grew into colonies. Consistent 45 
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with the flow cytometry results, cells retained their initial states for the full 6-day duration of the 
experiment in almost every colony (153/157) (Fig. 4C, Fig. S9, Movie S5).  
Like MultiFate-2, the number and stability of different states in MultiFate-3 can be modulated. In 
the model, reducing protein stability repeatedly bifurcates the system from type II septastability (7 
stable states) through hexastability (6 stable states) to tristability (3 stable states) (Fig. 1D). This 5 
process resembles the progressive loss of cell fate potential during stem cell differentiation (63–
66).  
To experimentally test this prediction, we transferred cells in each of the 7 states cultured under 
the High (100 nM) TMP (high protein stability) condition to similar media with Intermediate (40 
nM) or Low (10 nM) TMP conditions. As predicted by the model, the Intermediate TMP condition 10 
destabilized only the A+B+C state, but not the other 6 states (Fig. 4B, Intermediate TMP columns, 
Fig. S11), while the Low TMP condition destabilized all multi-protein states, preserving only those 
in which a single transcription factor is expressed (Fig. 4B, Low TMP columns, Fig. S12A). 
Consistent with the model, these transitions were also irreversible: restoring High TMP 
concentrations did not cause cells to repopulate previously destabilized states (Fig. S14). Taken 15 
together, these results demonstrate that the MultiFate-3 circuit supports septastability, and allows 
controlled bifurcations to produce irreversible cell state transitions.  
Can the MultiFate architecture be expanded beyond three transcription factors? In principle, with 
larger numbers of transcription factors, accumulation of basal expression could limit the ability of 
any transcription factor species to reach sufficiently high concentrations. Additionally, even if 20 
more stable states are generated, many could have relatively small attractor basins, rendering them 
effectively inaccessible. To find out how higher order MultiFate systems behave, we modeled 
circuits containing up to 11 transcription factor species, using the same parameter values 
established for MultiFate-2 and MultiFate-3. Even in larger MultiFate circuits, basal expression of 
more transcription factors did not curtail multistability. In fact, the number of stable fixed points 25 
grew nearly exponentially with the number of transcription factors, N, approaching a limiting 
function of 2N (Fig. 4D). To assess the accessibility of these states, we quantified their attractor 
basin volumes, defining states as “accessible” when their attractor basins were at least 25% as 
large as the maximal basin of other fixed points in the same system. Remarkably, most of the stable 
fixed points were accessible. For instance, with N=11 transcription factors, 1474 of the 1981 stable 30 
fixed points were accessible. More generally, the number of accessible fixed points grew 
monotonically with N, at a rate approaching that of the total number of fixed points (Fig. 4D, Fig. 
S15). These results indicate that the MultiFate architecture can be expanded to generate large 
numbers of accessible stable states.  
Discussion	35 
The astonishing diversity of cell types in our own bodies underscores the critical importance of 
multistable circuits and provokes the fundamental question of how to engineer a robust, 
controllable, and expandable synthetic multistable system. Here, we took inspiration from two 
ubiquitous features of natural multistable systems, namely competitive protein-protein interactions 
and transcriptional autoregulation, to design a synthetic multistable architecture that operates in 40 
mammalian cells. The MultiFate circuits introduced here exhibit many of the hallmarks of natural 
cell fate control systems. They generate as many as seven molecularly distinct, mitotically 
heritable cell states from three transcription factors (Fig. 3 and 4). They allow controlled switching 
of cells between states with transient transcription factor expression (Fig. 3F), similar to fate 
reprogramming (67). They support modulation of state stability (Fig. 3 and 4) and permit 45 
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irreversible (hysteretic) cellular transitions through externally controllable parameters such as 
protein stability (Fig. 3E, Fig. S14), similar to the irreversible loss of cell fate potential during stem 
cell differentiation (68, 69). Finally, implementing cross-inhibition at the protein levels makes 
MultiFate expandable, allowing one to exponentially increase the number of states in the system 
by ‘plugging in’ additional transcription factors, without re-engineering the existing circuit, a 5 
useful feature for synthetic biology. The same design principle may play a related role in natural 
systems, allowing the emergence of new cell states through transcription factor duplication and 
subfunctionalization in a manner analogous to the stepwise expansion of MultiFate circuits 
demonstrated here (32, 70–76).  
A remarkable feature of this circuit is its close agreement with predictions from a dynamical 10 
systems model (Box 1). Despite a lack of precise quantitative parameter values for many molecular 
interactions, the qualitative behaviors possible with this circuit design can be enumerated and 
explained from simple properties of the components and their interactions. More precise 
measurements of effective biochemical parameters and stochastic fluctuations could help to 
explain, eliminate, or exploit asymmetries (Fig. 3C and Fig. 4B) and provide a better understanding 15 
of the timescales of state transitions.  
MultiFate has a relatively simple structure, requiring a modest number of genes, all of the same 
type, yet exhibits robust memory behaviors, scalability, and predictive design. Future work should 
extend MultiFate into a full-fledged synthetic cell fate control system, in which extrinsic signals 
can be used to navigate cells sequentially through a series of fate choices, recapitulating cell 20 
behaviors associated with normal development. Coupling MultiFate to synthetic signaling systems 
such as synNotch (77, 78), MESA (79), synthekines (80), orthoIL-2/2R (81), engineered GFP (82) 
and auxin (83) should enable flexible and orthogonal control. MultiFate could also allow 
engineering of multicellular cell therapeutic programs. For example, one could engineer a stem-
like state that can either self-renew or “differentiate” into other states that recognize and remember 25 
different input signals and communicate with one another via signaling to coordinate complex 
response programs. Such strategies will benefit from the ability of MultiFate to allow probabilistic 
differentiation into multiple different states in the same condition (Fig. 3C, 4B). In this way, we 
anticipate that the MultiFate architecture will provide a scalable foundation for exploring the 
circuit-level principles of cell fate control and enabling new multicellular applications in synthetic 30 
biology.  
Box 1. Design of the MultiFate circuit 
Here we introduce the mathematical model of the MultiFate circuit and show how it can be used 
to design the experimental system and predict its behavior. For simplicity, we focus on a symmetric 
MultiFate-2 circuit whose two transcription factors share identical biochemical parameters and 35 
differ only in their DNA binding site specificity. A similar analysis of systems with more 
transcription factors and asymmetric parameters is presented in Supplementary Materials. 
We represent the dynamics of protein production and degradation using ordinary differential 
equations (ODEs) for the total concentrations of the transcription factors A and B, denoted [𝐴!"!] 
and [𝐵!"!], respectively. We assume that the rate of production of each protein follows a Hill 40 
function of the corresponding homodimer concentration, [𝐴#] or [𝐵#], with maximal rate β, Hill 
coefficient 𝑛, and half-maximal activation at a homodimer concentration of 𝐾$. A low basal rate 
of “leaky” protein production, denoted α, is included to allow self-activation from low initial 
expression states. Finally, each protein can degrade and dilute (due to cell division) at a total rate 
δ, regardless of its dimerization state. To simplify analysis, we non-dimensionalize the model by 45 
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rescaling time in units of δ%&, and concentrations in units of 𝐾$ (Supplementary Materials). We 
can then write: 
𝑑[𝐴!"!]









Dimerization dynamics occur on a faster timescale than protein production and degradation (84). 5 
This separation of timescales permits us to assume that the distribution of monomer and dimer 
states remains close to their equilibrium values, generating the following relationships between the 
concentrations of monomers, [𝐴] and [𝐵], and dimers, [𝐴#], [𝐵#], and [𝐴𝐵]: 
[𝐴]# = 𝐾([𝐴#] 
[𝐵]# = 𝐾([𝐵#] 10 
2[A][B] = K![AB] 
Here, because the two transcription factors share the same dimerization domain, homo- and hetero-
dimerization are assumed to occur with equal dissociation constants, 𝐾(. Additionally, 
conservation of mass implies that [𝐴!"!] = [𝐴] + [𝐴𝐵] + 2[𝐴#], with a similar relationship for B. 
Introducing the equilibrium equations given above into this conservation law produces expressions 15 
for the concentrations of the activating homodimers in terms of the total concentrations of A and 
B (which do not change form after non-dimensionalization):  
[𝐴#] =
2[𝐴!"!]#




𝐾( + 4([𝐴!"!] + [𝐵!"!]) + 5𝐾(# + 8([𝐴!"!] + [𝐵!"!])𝐾(
 
Inserting these expressions into the differential equations for [𝐴!"!] and [𝐵!"!] above, we obtain a 20 
pair of coupled ordinary differential equations with only [𝐴!"!] and [𝐵!"!] as variables.  
To understand the behavior of this system in physiologically reasonable parameter regimes (Table 
S4, Supplementary Materials), we used standard approaches from dynamical systems analysis 
(85). We plotted the nullclines (Fig. 1C, solid lines), defined by setting each of the ODEs above to 
zero. We then identified fixed points at nullcline intersections, and determined their linear stability 25 
(Fig. 1C, black and white dots) (85). Finally, we delineated the basins of attraction for each stable 
fixed point (Fig. 1C, shaded regions).  
Using this analysis, we identified parameter values that support type II tristability, a regime that 
minimally embodies the developmental concept of multilineage priming (42–50), and permits 
transitions to a bistable regime in response to tuning of a single parameter, thus allowing one to 30 
explore bifurcation dynamics (Fig. 1C, Fig. S1B). Stronger self-activation (higher values of β) was 
more likely to produce type II tristability (Fig. S1B, β row and column). Too much leaky 
production (high α) allowed both transcription factors to self-activate, reducing the degree of 
multistability, while too little (low α) stabilized the undesired OFF state (Fig. S1B, α column). 
Strong dimerization (low 𝐾() was essential for type II tristability (Fig. S1B, 𝐾( row and column). 35 
Finally, a broad range of Hill coefficients 𝑛 ≥ 1 were compatible with type II tristability. While 
higher values of 𝑛 led to a reduced sensitivity to other parameters and allowed the system to 
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tolerate higher values of α, they also stabilized the OFF state (Fig. S1B, 𝑛 row and column). 
Together, these results suggested that an ideal design would maximize β, minimize 𝐾(, and use 
intermediate values of α and 𝑛.  
Based on these conclusions, we incorporated multiple repeats of the homodimeric binding sites to 
maximize β, used strongly associating FKBP12F36V homodimerization domains (60) to minimize 5 
𝐾(, and modified the promoter sequences to allow some leaky expression to optimize α 
(Supplementary Materials). Finally, while we did not directly control 𝑛, we expected that the 
repeated homodimeric binding sites should lead to modest ultrasensitivity (86). These design 
choices produced the selected type II tristability in the experimental system (Fig. 3C, 
Supplementary Materials). 10 
A key feature of the MultiFate design is its ability to qualitatively change its multistability 
properties through bifurcations in response to parameter changes. In particular, the mathematical 
model predicts that protein stability can control the number of stable fixed points in phase space. 
In the non-dimensionalized model, the protein degradation rate, δ, does not appear explicitly but 
enters through the rescaling of α and β by (δ𝐾$)%& (see “non-dimensionalization of MultiFate 15 
model” section in Supplementary Materials). Thus, tuning protein stability is equivalent to 
multiplying both α and β by a common factor, which we term the “protein stability factor”. 
Reducing protein stability shifts the nullclines closer to the origin, causing the two unstable fixed 
points to collide with the stable A+B fixed point in a subcritical pitchfork bifurcation (Fig. 1 and 
Fig. S1B, “protein stability factor” column) (87). The result is a bistable system with A-only and 20 
B-only stable fixed points at somewhat lower concentrations (Fig. 1C). To experimentally realize 
this bifurcation, we designed the circuit to allow external control of transcription factor protein 
stability using the drug-inducible DHFR degron (Fig. 2C). As predicted, reducing protein stability 
destabilized the A+B state, but preserved the A-only and B-only stable states.  
In this way, model-based design enabled us to rationally engineer tristability as well as externally 25 
controllable transitions to bistability in the experimental system (Fig. 3C, Fig. 3E). The model 
presented above also generalizes in a straightforward manner to allow analysis of expanded 
MultiFate circuits (Fig. 1D, Supplementary Materials).  
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Fig. 1. The naturally-inspired MultiFate architecture generates diverse types of 
multistability in the model. 	
(A) An ideal synthetic multistable circuit should generate multiple stable states, represented by 
colored cell cartoons (upper level) and attractors in the phase space of transcription factor 
expression (lower level, schematic, TF A-C on coordinate axes represent transcription factor 5 
concentrations); support control of state-switching (left); and state stability (middle); and allow 
easy expansion of states by addition of more transcription factors (right). (B) Competitive protein-
protein interactions and autoregulatory feedback are prevalent in natural multistable circuits that 
control myogenesis (left) and endodermal differentiation (right). These simplified and abridged 
diagrams highlight the role of transcriptional autoregulation and promiscuous dimerization in these 10 
circuits. Blue arrows indicate competitive protein-protein interactions, which can involve higher 
order multimerization. Orange dashed arrows indicate direct or indirect positive transcriptional 
feedback. (C, D) Models of the MultiFate-2 circuit and MultiFate-3 circuit (Box 1, Supplementary 
Materials) generates diverse types of multistability in different parameter regimes (indicated above 
plots). In the model of the MultiFate-3 circuit, reduced protein stability generates 4 stable states 15 
(type I quadrastability), but the state in which all transcription factors are OFF has a very small 
attractor basin, and thus should be effectively unstable in the presence of biological noise. 
Therefore only 3 states should be experimentally stable in a low protein stability regime, consistent 
with experimental results in Fig. 4B, Low TMP columns. Complete lists of multistability regimes 
are shown in Fig. S1 and S2. For both panels, each axis represents the total concentration of each 20 
transcription factor. All models used here are non-dimensionalized, with 𝐾( = 1 and 𝑛 = 1.5. 
Note that in the non-dimensionalized model, changing protein stability is equivalent to multiplying 
and with the same factor (Box 1). 
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Fig. 2 Engineered transcription factors enable homodimer-dependent autoregulation and 
heterodimerization-based mutual inhibition.	
(A) Zinc finger transcription factors can generate homodimer-dependent activation. (Left) 
Schematic representations of test constructs, in which ZF DNA-binding domains (ErbB2ZF  (56), 
red circle) fused to activation (VP48, AD) and in some cases dimerization (GCN4, blue squiggle) 5 
domains bind to corresponding target sites (red pads) to activate reporter expression (Citrine). 
Activators (Table S1) were expressed from a constitutive CAG promoter (87), and co-transfected 
with a Citrine fluorescence reporter that has 2 repeats of 18bp tandem binding site pairs at the 
promoter. (Right) Arginine-to-alanine mutations in the ErbB2ZF domain modulated reporter 
activation by ZF-GCN4-AD and ZF-AD. The R2AR39A variant was selected due to high ZF-10 
GCN4-AD activation and minimal ZF-AD activation. Fold activation is defined in Fig. S4A. WT 
= wild-type variant. (B) Using FKBP12F36V (FKBP) as the homodimerization domain (light cyan 
partial box), activation can be controlled by AP1903 (blue circle) in a dose-dependent manner. 
Orange circle = BCRZFR39A. (C) Transcription factor self-activation can be controlled by TMP 
and AP1903. (Left) Design of the controllable self-activation circuit (Table S1). (Right) Stable 15 
polyclonal cells showed bimodal mCitrine distribution upon circuit activation. An empirical 
threshold at mCitrine=104 separates the population into mCitrine- and mCitrine+ subpopulations, 
and the mCitrine+ fraction normalized to constitutive Dox treatment group (Dox+, gray curve) 
was used to quantify self-activation strength (Supplementary Materials). Colored arrows indicate 
data from the middle panel. IRES = internal ribosome entry site; PEST = constitutive degradation 20 
tag; (D) Self-activation was inhibited by competing transcription factors with a different ZF and 
matching dimerization domains. Two monoclonal stable lines could spontaneously turn on self-
activation in media containing AP1903 and TMP (Table S2). Perturbation is introduced into 
monoclonal lines by stably integrating plasmids expressing different transcription factor variants 
into monoclonal lines (Supplementary Materials). Red circle = 42ZFR2AR39AR67A; Green circle 25 
= BCRZFR39A. In all panels, each dot represents one replicate, and each red line or bar indicates 
the mean of replicates. 
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Fig. 3 Experimental data show that MultiFate-2 generates multiple stable states, supports 
modulation of state stability and allows state-switching. 	
(A) The experimental MultiFate-2 design uses two self-activation cassettes differ only in their ZF 
DNA-binding domains and binding sites, and fluorescent proteins. Each cassette expresses FKBP-
ZF-VP16-DHFR-IRES-FP-PEST, where ZF represents either BCRZFR39A or 5 
37ZFR2AR11AR39AR67A and FP represents either mCherry or mCitrine, for A and B, 
respectively.  Detailed construct maps and differences among MultiFate-2 lines are available in 
Table S1 and Table S2. (B) MultiFate-2.1 cells spontaneously activate A, B or both cassettes upon 
addition of 100 nM AP1903 and 10 µM TMP. Cell percentages in OFF, A-only, B-only and A+B 
states were quantified and plotted as a square with four colored circles representing the percentage 10 
of cells in each quadrant (Supplementary Materials). (C) Three MultiFate-2 lines exhibited type II 
tristability in the High TMP condition, and bistability in the Low TMP condition. In all conditions, 
AP1903 concentration is 100 nM. Exact concentrations of TMP are shown in Fig. S6-8. Unstable 
states, defined by states having more than 10% cells escaping after 18 days, were marked in pink 
rectangles. (D) A-only, B-only and A+B states were each stable during growth from single 15 
MultiFate-2.3 cells into colonies over 5 days under a time-lapse microscope. Scale bar: 500 µm 
for the wide field image (left), 100 µm for zoomed in images (right). (E) Escape from the 
destabilized A+B state was irreversible, as shown by both modeling (Movie S3), and experiment 
using MultiFate-2.1 cells. (Top) The model used here is non-dimensionalized, with 𝐾( = 1 and 
𝑛 = 1.5. Simulated cells on phase portraits were calculated using the Gillespie stochastic 20 
simulation algorithm (89) (Supplementary Materials). (Bottom) The Day 0 and Day 18 squares are 
the same with those in panel C (MultiFate-2.1, A+B initial state under Low TMP), since data are 
from the same experiment. (F) MultiFate-2.3 cells can be switched between states by transient 4-
OHT or Dox treatment. Cells were cultured in 100 nM AP1903 + 30 nM TMP (Low TMP 
condition) throughout the experiment. 4-OHT = 25 nM, Dox = 500 ng/ml. In all panels, initial A-25 
only, B-only and A+B cells were sorted from a population of cells in different states, while initial 
OFF cells came from cells in regular CHO media without any inducers. Each square represents the 
mean fractions of three replicates. 
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Fig. 4 MultiFate architecture is expandable to include three and potentially even more 
transcription factors.	
(A) The experimental MultiFate-3 design uses three self-activation cassettes differ only in their 
ZF DNA-binding domains and binding sites, and fluorescent proteins. Each cassette expresses 
FKBP-ZF-VP16-DHFR-IRES-FP-PEST, where ZF represents either BCRZFR39A, 5 
37ZFR2AR11AR39AR67A or ErbB2ZFR2AR39A, and FP represents either mCherry, mCitrine 
or mTurquoise2, for A, B and C, respectively. Detailed construct maps are available in Table S1. 
(B) The MultiFate-3 line exhibited type II septastability, hexastability and tristability in three 
different TMP conditions. (Top) State percentages except OFF state percentage were then 
quantified and plotted as a hexagon with seven colored circles representing the percentage of cells 10 
in each octant (Supplementary Materials). OFF state percentages were usually low (<1%) across 
all conditions, and are separately labeled only when their fractions exceed 1%. (Bottom) High 
TMP condition = 100 nM AP1903 + 100 nM TMP; Intermediate TMP condition = 100 nM AP1903 
+ 40 nM TMP; Low TMP condition = 100 nM AP1903 + 10 nM TMP. Except for OFF state cells, 
cells in different initial states were sorted from a mixed population of cells in the High TMP 15 
condition. Initial OFF cells came from cells in regular CHO media without any inducers. Circle 
colors in each hexagon represent the mean percentages of three replicates. (C) Cells in each of the 
seven states were stable during growth from single cells into colonies over 6 days under a time-
lapse microscope. Scale bar: 500 µm for the wide field image (left), 100 µm for zoomed in images 
(right). (D) MultiFate can be expanded (model). The number of accessible stable fixed points 20 
grows monotonically with the number, N, of transcription factors species in the model. An 
accessible stable fixed point is defined as a stable fixed point that has an attractor basin volume 
that is at least 25% of maximal attractor basin volume of stable fixed points in the same system 
(same N). The parameter set provided above the plot is the same non-dimensionalized parameter 
set used in MultiFate-2 and MultiFate-3 models under high protein stability. 25 
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